|Day Low/High||74.51 / 78.11|
|52 Wk Low/High||28.82 / 84.37|
The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.
-- The Company will award 10 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --
With few catalysts for the markets, Tuesday's special election for a Pennsylvania congressional seat could set the tone this week.
I'll be watching for entry points to develop this afternoon.
The best way to deal with the struggling market is selective stock picking and good defense.
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
It is important to note that watching for a reversal is much different than being short.
If we have a little consolidating action here the buyers will start pushing again.
Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.
What drives the trading action are structural issues, not macroeconomic news events or political drama.
Duchenne Organizations Led by Parent Project Muscular Dystrophy Help Fund Next Step in Cutting-Edge Treatment
There is still a very strong appetite for individual stocks with momentum.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.